All about the National surveillance of HPV vaccination programme

The national surveillance of the HPV vaccination programme is monitoring the effectiveness, safety and vaccine uptake of the HPV vaccination programme.

The effectiveness of the vaccine is evaluated through the national surveillance of the HPV vaccination programme. Since 2017, the incidence of HPV genotypes in cervical cancer and precursors to cervical cancer is monitored in MSIS.

The first cohort of girls offered the HPV vaccine in the 7th grade has a significantly lower prevalence of human papillomavirus (HPV) than girls in older cohorts who were not eligible for HPV vaccination.

Cervical cancer could be almost eradicated in Norway by the year 2039 thanks to an effective vaccine and the world's highest vaccination coverage, according to a new study.

The national surveillance programme was established to monitor the vaccine uptake, effectiveness and safety of the HPV immunisation programme.

A complete overview of all publications from the HPV surveillance programme.

A study shows that girls receiving one or more doses of HPV vaccine have no greater risk of chronic fatigue syndrome/myalgic encephalomyelitis (CFS / ME) than unvaccinated girls.